2022 / 01

Next Paper
DOI: 10.24075/brsmu.2022.005

ORIGINAL RESEARCH

Properties of RBD specific IgG from COVID-19 patients and Sputnik V vaccinated individuals

Generalova LV1, Grigoriev IV2, Vasina DV2, Tkachuk AP2, Kruzhkova IS2, Kolobukhina LV2, Burgasova OA1,2, Gushchin VA2
About authors

1 Рeoples’ Friendship University of Russia (RUDN University), Moscow, Russia

2 Gamaleya National Research Center for Epidemiology and Microbiology, Moscow, Russia

Correspondence should be addressed: Vladimir A. Gushchin
Gamaleya, 18, str. 9, Moscow, Russia; moc.liamg@adainawow

About paper

Funding: this research was funded by the Ministry of Health of the Russian Federation, Government assignments number № АААА - А20-120113090054-6, Prof. Olga A. Burgasova was also supported by the RUDN University Strategic Academic Leadership Program.

Author contribution: LV Generalova, IV Grigoriev — research planning, experiments preparation and execution, data interpretation and paper draft preparation; IS Kruzhkova, LV Kolobukhina — data interpretation and paper draft preparation; DV Vasina, AP Tkachuk, OA Burgasova, VA Gushchin — research planning, data interpretation and paper draft preparation.

Compliance with ethical standards: the study was approved by the ethics committee of the First Moscow Infectious Diseases Hospital (protocol № 11/А dated November 16, 2020); informed consent was obtained from all study participants.

Received: 2022-01-23 Accepted: 2022-02-08 Published online: 2022-02-16
|
  1. Benner SE, Patel EU, Laeyendecker O, et al. SARS-CoV-2 antibody avidity responses in COVID-19 patients and convalescent plasma donors. J Infect Dis. 2020; 222: 1974–84.
  2. Tang J, Grubbs G, Lee Y, et al. Impact of convalescent plasma therapy on SARS-CoV-2 antibody profile in COVID-19 patients. Clin Infect Dis. 2021; ciab317.
  3. Baker KF, Hanrath AT, Schim van der Loeff I, et al. National Early Warning Score 2 (NEWS2) to identify inpatient COVID-19 deterioration: a retrospective analysis. Clin Med (Lond). 2021; 21 (2): 84–89.
  4. Paul KS Chan, Pak-Leong Lim, Esther YM Liu, et al. Antibody Avidity Maturation during Severe Acute Respiratory Syndrome– Associated Coronavirus Infection. J Infect Dis. 2005; 192 (1): 166–9.
  5. Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020; 11 (1): 2251.
  6. Long Q, Liu B, Deng H, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020; 26 (6): 845–8.
  7. Kreer C, Zehner M, Weber T, et al. Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients. Cell. 2020; 182 (4): 843–54.
  8. Chi X, Yan R, Zhang J, et al. A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2. Science. 2020; 369 (6504): 650–5.
  9. Piccoli L, Park Y, Tortorici M, et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 Spike ReceptorBinding Domain by structure-guided high-resolution serology. Cell. 2020; 183 (4): 1024–42.
  10. Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021; 591, 639–44.